MIF loss impairs Myc-induced lymphomagenesis

Cell Death and Differentiation

Volumn 12, Issue 10, 2005, Pages 1319-1328

  Talos, F ^a   Mena, P ^a   Fingerle Rowson, G ^b   Moll, U ^a   Petrenko, O ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ARF; DNA replication; E2F1; Inflammation; p53

Indexed keywords

ARF PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN P53; TRANSCRIPTION FACTOR E2F;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; GENE DELETION; GENE INACTIVATION; INFLAMMATION; MOUSE; NONHUMAN; ONCOGENE MYC; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; FEMALE; GENE DELETION; GENE EXPRESSION; GENES, MYC; IN SITU NICK-END LABELING; LYMPHOMA, B-CELL; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 27144516430     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401653     Document Type: Article

References (66)

1. Calandra T and Roger T (2003) Macrophage migration inhibitory factor: A regulator of innate immunity. Nat. Rev. Immunol. 3: 791-800
2. Kobayashi S, Satomura K, Levsky JM, Sreenath T, Wistow GJ, Semba I, Shum L, Slavkin HC and Kulkarni AB (1999) Expression pattern of macrophage migration inhibitory factor during embryogenesis. Mech. Dev. 84: 153-156
3. Suzuki T, Ogata A, Tashiro K, Nagashima K, Tamura M and Nishihira J (1999) Augmented expression of macrophage migration inhibitory factor (MIF) in the telencephalon of the developing rat brain. Brain Res. 816: 457-462
4. Wistow GJ, Shaughnessy MP, Lee DC, Hodin J and Zelenka PS (1993) A macrophage migration inhibitory factor is expressed in the differentiating cells of the eye lens. Proc. Natl. Acad. Sci. USA 90: 1272-1275
5. David JR (1966) Delayed hypersensitivity [i#in vitro#1i]: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. USA 56: 72-77
6. Arcuri F, Ricci C, Ietta F, Cintorino M, Tripodi SA, Cetin I, Garzia E, Schatz F, Klemi P, Santopietro R and Paulesu L (2001) Macrophage migration inhibitory factor in the human endometrium: Expression and localization during the menstrual cycle and early pregnancy. Biol. Reprod. 64: 1200-1205
7. Morelli AE, Zahorchak AF, Larregina AT, Colvin BL, Logar AJ, Takayama T, Falo LD and Thomson AW (2001) Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 5: 1512-1523
8. Morimoto T, Nishihira J and Kohgo T (2003) Immunohistochemical localization of macrophage migration inhibitory factor (MIF) in human gingival tissue and its pathophysiological functions. Histochem. Cell. Biol. 120: 293-298
9. Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, Ishibashi T and Shimizu H (2002) Histochemical analysis of macrophage migration inhibitory factor in psoriasis vulgaris. Histochem. Cell. Biol. 118: 251-257
10. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A and Bucala R (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 6544: 68-71
11. Metz CN and Bucala R (2000) MIF In [i#Cytokine Reference#1i] Vol. I, Oppenheim J and Feldmann M, eds (New York: Academic Press) pp. 703-717
12. Campa MJ, Wang MZ, Howard B, Fitzgerald MC and Patz Jr EF (2003) Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res. 63: 1652-1656
13. Markert JM, Fuller CM, Gillespie GY, Bubien JK, McLean LA, Hong RL, Lee K, Gullans SR, Mapstone TB and Benos DJ (2001) Differential gene expression profiling in human brain tumors. Physiol. Genomics 7: 21-33
14. Meyer-Siegler K (2000) Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J. Interferon Cytokine Res. 20: 769-778
15. Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T and Sugimachi K (2002) Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin. Cancer Res. 8: 3755-3760
16. White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB and Arenberg DA (2003) Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: Role in angiogenesis and prognosis. Clin. Cancer Res. 9: 853-860
17. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ and Beach DH (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190: 1375-1382
18. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J and Bucala R (2002) Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA 99: 345-350
19. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H and Bernhagen J (2000) Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408: 211-216
20. Cope GA and Deshaies RJ (2003) COP9 signalosome: A multifunctional regulator of SCF and other cullin-based ubiquitin ligases. Cell 114: 663-671
21. Tomoda K, Yoneda-Kato N, Fukumoto A, Yamanaka S and Kato JY (2004) Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. J. Biol. Chem. 279: 43013-43018
22. Wolf DA, Zhou C and Wee S (2003) The COP9 signalosome: An assembly and maintenance platform for cullin ubiquitin ligases? Nat. Cell. Biol. 12: 1029-1033
23. Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R, Moll U, Muller W and Bucala R (2003) The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc. Natl. Acad. Sci. USA 100: 9354-9359
24. Petrenko O, Fingerle-Rowson G, Peng T, Mitchell RA and Metz CN (2003) Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. J. Biol. Chem. 278: 11078-11085
25. Petrenko O and Moll U (2005) Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol. Cell 17: 225-236
26. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD and Brinster RL (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538
27. Sidman CL, Denial TM, Marshall JD and Roths JB (1993) Multiple mechanisms of tumorigenesis in E mu-myc transgenic mice. Cancer Res. 53: 1665-1669
28. Li FX, Zhu JW, Hogan CJ and DeGregori J (2003) Defective gene expression, S-phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice. Mol. Cell. Biol. 23: 3607-3622
29. Nikiforov MA, Chandriani S, Park J, Kotenko I, Matheos D, Johnsson A, McMahon SB and Cole MD (2002) TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins. Mol. Cell. Biol. 22: 5054-5063
30. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ and Roussel MF(1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12: 2424-2433
31. Eischen CM, Weber JD, Roussel MF, Sherr CJ and Cleveland JL (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13: 2658-2669
32. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR and Lowe SW (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13: 2670-2677
33. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A and van Lohuizen M (1999) Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13: 2678-2690
34. Eischen CM, Woo D, Roussel MF and Cleveland JL (2001) Apoptosis triggered by Mycinduced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol. Cell Biol. 21: 5063-5070
35. Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A, Lees JA, Sherr CJ, Roussel MF and Cleveland JL (2003) Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol. Cell 11: 905-914
36. Rowland BD, Denissov SG, Douma S, Stunnenberg HG, Bernards R and Peeper DS (2002) E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53 induced proliferative arrest. Cancer Cell 2: 55-65
37. Secombe J, Pierce SB and Eisenman RN (2004) Myc: A weapon of mass destruction. Cell 117: 153-166
38. Sugimoto M, Kuo ML, Roussel MF and Sherr CJ (2003) Nucleolar Art tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 11: 415-424
39. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ and Zambetti GP (2000) p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 14: 2358-2365
40. +/- mice. Proc. Natl. Acad. Sci. USA 99: 16865-16870
41. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ and Lowe SW (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12: 2434-2442
42. Kamijo T, van de Kamp E, Chong MJ, Zindy F, Diehl JA, Sherr CJ and McKinnon PJ (1999) Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res. 59: 2464-2469
43. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM and Lowe SW (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335-346
44. Dang J, Kuo ML, Eischen CM, Stepanova L, Sherr CJ and Roussel MF (2002) The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res. 62: 1222-1230
45. Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon-Cardo C and Lowe SW (2003) Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res. 63: 5703-5706
46. Bartel F, Taubert H and Harris LC (2002) Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2: 9-15
47. Perry ME, Mendrysa SM, Saucedo LJ, Tannous P and Holubar M (2000) p76(MDM2) inhibits the ability of p90(MDM2) to destabilize p53. J. Biol. Chem. 275: 5733-5738
48. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Water CM, Penn LZ and Hancock DC (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128
49. Ma D, Zhou P and Harbour JW (2003) Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb. J. Biol. Chem. 278: 19358-19366
50. Santoni-Rugiu E, Falck J, Mailand N, Bartek J and Lukas J (2000) Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol. Cell. Biol. 20: 3497-3509
51. Wymann D, Bluggel M, Kalbacher H, Blesken T, Akdis CA, Meyer HE and Blaser K (1999) Human B cells secrete migration inhibition factor (MIF) and present a naturally processed MIF peptide on HLA-DRB1*0405 by a FXXL motif. Immunology 96: 1-9
52. Abe R, Peng T, Sailors J, Bucala R and Metz CN (2001) Regulation of the CTL response by macrophage migration inhibitory factor. J. Immunol. 166: 747-753
53. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA and Bucala R (2003) MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197: 1467-1476
54. Roger T, David J, Glauser MP and Calandra T (2001) MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414: 920-924
55. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, Park CH, Giangrande P, Wu L, Saavedra HI, Field SJ, Thompson MA, Yang H, Fujiwara Y, Greenberg ME, Orkin S, Smith C and Nevins JR (2001) Myc requires distinct E2F activities to induce S phase and apoptosis. Mol. Cell 8: 105-113
56. Santoni-Rugiu E, Duro D, Farkas T, Mathiasen IS, Jaattela M, Bartek J and Lukas J (2002) E2F activity is essential for survival of Myc-overexpressing human cancer cells. Oncogene 21: 6498-6509
57. Sherr CJ (2004) Principles of tumor suppression. Cell 116: 235-246
58. Cleveland JL and Sherr CJ (2004) Antagonism of Myc functions by Art. Cancer Cell 4: 309-311
59. Trimarchi JM and Lees JA (2002) Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell. Biol. 3: 11-20
60. DeGregori J (2002) The genetics of the E2F family of transcription factors: Shared functions and unique roles. Biochim. Biophys. Acta. 1602: 131-150
61. Harbour JW and Dean DC (2000) The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev. 14: 2393-2409
62. Zhang HS, Postigo AA and Dean DC (1999) Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 97: 53-61
63. Rounbehler RJ, Rogers PM, Conti CJ and Johnson DG (2002) Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model. Cancer Res. 62: 3276-3281
64. Phillips AC, Ernst MK, Bates S, Rice N and Vousden KH (1999) E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol. Cell 4: 771-781
65. Hsieh JK, Fredersdorf S, Kouzarides T, Martin K and Lu X (1997) E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 11: 1840-1852
66. Phillips AC, Bates S, Ryan KM, Helin K and Vousden KH (1997) Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev. 11: 1853-1863